Jiangxi Synergy Pharmaceutical Receives China Approval for Type 2 Diabetes Tablets


Idag, 13:14

07:14 AM EDT, 05/19/2026 (MT Newswires) -- China's drug regulator approved Jiangxi Synergy Pharmaceutical's (SHE:300636) empagliflozin tablets, according to an after-hours filing on Monday with the Shenzhen bourse.

Shares rose 1% during the close of trading Tuesday.

The drug is indicated for type 2 diabetes patients.

Marknadsöversikt

1 DAG %

Senast

1 mån